PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up

Operti, Maria Camilla; Bernhardt, Alexander; Grimm, Silko; Engel, Andrea; Figdor, Carl G.; Tagit, Oya

doi:10.1016/j.ijpharm.2021.120807

Cited by 138 publications

(99 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently undergoing Phase III clinical trials for access to the EU and US markets. For the NPs, only one Phase II clinical trial based on PEG-PLGA/PLA-PEG NPs (BIND-014) for metastatic castration-resistant prostate cancer was reported [ 15 ]. However, in the case of NDDs treatment, no PLGA NPs are currently on the market or in clinical trials, but are currently only at the preclinical stage [ 16 ].…”

Section: Plga Npsmentioning

confidence: 99%

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

et al. 2021

View full text Add to dashboard Cite

Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).

show abstract

Section: Plga Npsmentioning

confidence: 99%

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…PLGA micro/nanoparticle have a variety of morphological structures, including solid, porous, core-shell structure and multi-compartment particles. Porous particles and core-shell particles are the most widely used types at present, and they can realize the co-delivery of multiple drugs [11,58]. Single-layer polymer carriers prepared based on PLGA are widely used to deliver hydrophilic or hydrophobic drugs [59].…”

Section: Types Of Plga Micro/nanoparticlementioning

confidence: 99%

“…Developing an efficient drug delivery system for cancer has become a research hotspot in the biomedical field [11]. Researchers have prepared various micro/nanoparticle as delivery vehicle [12], breaking through the restriction of free drug applications [13].…”

Section: Introductionmentioning

confidence: 99%

PLGA-based drug delivery system for combined therapy of cancer: research progress

et al. 2021

Mater. Res. Express

View full text Add to dashboard Cite

In recent years, PLGA micro/nano particle drug delivery systems has been widely used in cancer treatment. According to the unique properties of PLGA, carriers of various structures are designed to keep the function of drugs or bioactive substances, ensure the effective load of molecules and improve the bioavailability of drugs in diseased parts. PLGA is one of the earliest and most commonly used biodegradable materials. It is often used for functional modification with other polymers (such as polyethylene glycol and chitosan) or other molecules (such as aptamers and ligands) to deliver various small molecule drugs (such as DOX and DTX) and bioactive macromolecules (such as proteins and nucleic acids) to improve targeting, controlled release and therapeutic properties. In this paper, the preparation methods, physical and chemical properties and medical applications of PLGA micro/nano particles are discussed. We focused on the recent research progress of the PLGA-based drug carrier system in tumor combination therapy.

show abstract

“…Good manufacturing practices verification is required to ensure conformance in large-scale production [ 6 ]. In addition, to evaluate whether DDS large-scale production influences clinical performance, comprehensive quality controls of drug carriers are essential [ 8 ]. Finally, clinical trials are mandatory to determine the ratio between benefits and risks of the developed DDS [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings

et al. 2022

View full text Add to dashboard Cite

Clinically available medications face several hurdles that limit their therapeutic activity, including restricted access to the target tissues due to biological barriers, low bioavailability, and poor pharmacokinetic properties. Drug delivery systems (DDS), such as nanoparticles (NPs) and hydrogels, have been widely employed to address these issues. Furthermore, the DDS improves drugs’ therapeutic efficacy while reducing undesired side effects caused by the unspecific distribution over the different tissues. The integration of NPs into hydrogels has emerged to improve their performance when compared with each DDS individually. The combination of both DDS enhances the ability to deliver drugs in a localized and targeted manner, paired with a controlled and sustained drug release, resulting in increased drug therapeutic effectiveness. With the incorporation of the NPs into hydrogels, it is possible to apply the DDS locally and then provide a sustained release of the NPs in the site of action, allowing the drug uptake in the required location. Additionally, most of the materials used to produce the hydrogels and NPs present low toxicity. This article provides a systematic review of the polymeric NPs-loaded hydrogels developed for various biomedical applications, focusing on studies that present in vivo data.

show abstract

PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up

Cited by 138 publications

References 118 publications

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

PLGA-based drug delivery system for combined therapy of cancer: research progress

Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings

Contact Info

Product

Resources

About